New drug combo could tame autoimmune hepatitis and cut steroid use
NCT ID NCT06381453
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding belimumab to standard therapy can better control autoimmune hepatitis, a chronic liver disease. About 48 adults with active or stable disease will receive weekly injections for 72 weeks. The goal is to reduce liver inflammation and lower the need for steroids or other immune-suppressing drugs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEPATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
G.I Research Institute
RECRUITINGVancouver, British Columbia, Canada
-
London Health Sciences Centre
RECRUITINGLondon, Ontario, Canada
-
McMaster University
RECRUITINGHamilton, Ontario, Canada
-
Toronto General Hospital
RECRUITINGToronto, Ontario, M5G 2C4, Canada
-
University of Calgary
RECRUITINGCalgary, Alberta, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test may tame the tightrope walk of transplant drugs
- New blood test may sharpen diagnosis of autoimmune liver disease
- AI may solve tricky liver diagnosis puzzle
- Blood fats and nanoparticles may reveal hidden clues in autoimmune liver disease
- Vegan diet may tame autoimmune hepatitis in kids
- New drug aims to tame autoimmune hepatitis and cut steroid use